(Reuters) -The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck’s cancer drug to treat two types adrenal gland tumors.
The drug, Welireg, became the first FDA-approved oral treatment for the two tumors — pheochromocytoma and paraganglioma.
The regulator’s approval was based on a study in which Welireg showed an objective response rate of 20.6%. ORR is the percentage of people who have a partial response or complete response to the treatment within a certain period of time.
(Reporting by Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar)
Comments